Compare Hims and Hers Health Inc (HIMS) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.

VUSB trades at $49.66, up 0.04% on the day, with a bearish technical signal driven by moving averages and ADX readings. Recent dividends include $0.18 paid on July 6, 2026, and $0.17 scheduled for August 5, 2026. Financial ratios such as P/E and ROE are unavailable in the current data, limiting fundamental assessment.

The outlook is cautious due to bearish technical indicators and incomplete financial data. Risks include interest rate sensitivity, as highlighted by recent Fed commentary, and reliance on short-term bond performance. Investors should await updated financial disclosures for a clearer fundamental picture.